Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A2 | O15244 | 15/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.60 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2678807 | 1.00 | SLC22A2 (0.64) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL19177145 | 1.00 | SLC22A2 (0.64) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL30231732 | 1.00 | SLC22A2 (0.64) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL29464234 | 1.00 | SLC22A2 (0.64) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL80366 | 1.00 | SLC22A2 (0.64) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL19041037 | 1.00 | SLC22A2 (0.64) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL82075 | 1.00 | SLC22A2 (0.64) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL86352 | 1.00 | SLC22A2 (0.64) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL21356931 | 1.00 | SLC22A2 (0.64) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL81764 | 0.99 | SLC22A2 (0.64) | SLC22A2CYP3A4TMEM97ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376080-B1 | SYNTHESIS OF CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS AND INTERMEDIATES | SHIONOGI & CO (JP) | 2017-09-13 | — | — | EP | disclosed |
| EP-3127542-A1 | ANTIVIRAL THERAPY | VIIV Healthcare Company (US) | 2017-02-08 | — | — | EP | disclosed |
| EP-2932970-A1 | ANTIVIRAL THERAPY | VIIV Healthcare Company (US) | 2015-10-21 | — | — | EP | disclosed |
| WO-2011094150-A1 | ANTIVIRAL THERAPY | GLAXOSMITHKLINE LLC (US) | 2011-08-04 | — | — | WO | disclosed |